

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody or an anti NCA-95 antibody.
2. (Original) The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody.
3. (Original) The method of claim 2, wherein said anti-NCA-90 antibody is MN-3.
4. (Original) The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-95 antibody.
5. (Currently Amended) The A method of claim 1 for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody, wherein said anti-granulocyte antibody is selected from the group consisting of MN-2, MN-3, MN-15, NP-1 and NP-2.
6. (Withdrawn)
7. (Currently Amended) The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal ~~antibody~~ antibody, chimeric antibody, humanized antibody and human antibody.
- 8.-17. (Withdrawn)

18. (Previously Amended) The method of claim 1, wherein said therapeutic composition comprises two or more naked anti-granulocyte antibodies.
19. (Previously Amended) The method of claim 1, further comprising administering an anti-CD33 antibody.
20. (Original) The method of claim 19, wherein said anti-CD33 antibody is M-195.
21. (Previously Amended) The method of claim 1, further comprising administering an anti-CD15 antibody.
- 22.-24. (Withdrawn)
25. (New) The method of claim 5, wherein said anti-granulocyte antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, humanized antibody and human antibody.
26. (New) The method of claim 5, wherein said therapeutic composition comprises two or more naked anti-granulocyte antibodies.
27. (New) The method of claim 5, further comprising administering an anti-CD33 antibody.
28. (New) The method of claim 27, wherein said anti-CD33 antibody is M-195.
29. (New) The method of claim 5, further comprising administering an anti-CD15 antibody.
-